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Immune mediated adverse drug reactions (IM-ADRs) remain a significant source of patient
morbidity that have more recently been shown to be associated with specific class I and/or
II human leukocyte antigen (HLA) alleles. Abacavir-induced hypersensitivity syndrome is a
CD8+ T cell dependent IM-ADR that is exclusively mediated by HLA-B*57:01. We and oth-
ers have previously shown that abacavir can occupy the floor of the peptide binding groove
of HLA-B*57:01 molecules, increasing the affinity of certain self peptides resulting in an al-
tered peptide-binding repertoire. Here, we have identified another drug, acyclovir, which ap-
pears to act in a similar fashion. As with abacavir, acyclovir showed a dose dependent
increase in affinity for peptides with valine and isoleucine at their C-terminus. In agreement
with the binding studies, HLA-B*57:01 peptide-elution studies performed in the presence of
acyclovir revealed an increased number of endogenously bound peptides with a C-terminal
isoleucine. Accordingly, we have hypothesized that acyclovir acts by the same mechanism
as abacavir, although our data also suggest the overall effect is much smaller: the largest
changes of peptide affinity for acyclovir were 2-5 fold, whereas for abacavir this effect was
as much as 1000-fold. Unlike abacavir, acyclovir is not known to cause IM-ADRs. We con-
clude that the modest effect of acyclovir on HLA binding affinity in contrast to the large effect
of abacavir is insufficient to trigger a hypersensitivity syndrome. We further support this by
functional in vitro studies where acyclovir, unlike abacavir, was unable to produce an
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increase in IFN-γ upon expansion of HLA-B*57:01+ PBMCs from healthy donors. Using
abacavir and acyclovir as examples we therefore propose an in vitro pre-clinical screening
strategy, whereby thresholds can be applied to MHC-peptide binding assays to determine
the likelihood that a drug could cause a clinically relevant IM-ADR.
Introduction
Adverse drug reactions (ADRs) represent a significant health problem, and add significantly to
the cost of drug development. Immune mediated adverse drug reactions (IM-ADRs) are amongst
the most difficult to predict. Recently, an increasing number of studies have implicated specific
human leukocyte antigen (HLA) alleles with various IM-ADRs [1,2]. This is exemplified by the
strong association between the nucleoside reverse transcriptase inhibitor abacavir and a drug
hypersensitivity syndrome in individuals carrying HLA-B57:01, with a 55% positive predictive
value and 100% negative predictive value [3]. Our group and others have proposed the altered
repertoire hypothesis to explain abacavir-induced hypersensitivity [4–6]. In an earlier study, we
were able to illustrate that abacavir interacts with residues in the F-pocket of HLA-B57:01 which
are typically in contact with the side chain of the C-terminal residue of the bound peptide. This
results in an alteration of the specificity of HLA-B57:01 for self-peptides, and a corresponding
presentation of de-novo self-peptides with much higher affinities in the presence of the drug [4].
The assays performed to study the effect of abacavir on HLA binding could be utilized to screen
other drugs for potential effects on the self-peptide repertoire. This would provide a potential in
vitro screening strategy to identify drugs at highest risk of causing IM-ADRs in vivo when used in
human donors that express the affected HLAmolecules. Such an in vitro screen would be of high
value in the early phases of drug development as a typical phase I or II clinical trial would be un-
derpowered to ensure that every known (or even every common) HLAmolecule is represented at
sufficient frequency, particularly taking into account the incomplete positive predictive value of
any HLA allele for a specific IM-ADR. Thus severe HLA associated IM-ADRs are often only de-
tected when a drug comes into broad use and significant investment has already been made.
We have established two in vitro assays that are potentially suited to screen whether a drug can
alter the repertoire of HLA-bound self-peptides. The first is a purified HLA binding assay, which
can be used together with a positional scanning combinatorial peptide libraries (PSCPL) approach
to measure changes in the peptide-binding specificity in the presence or absence of the drug in
question. The second is a peptide elution assay performed on single HLA allele transfected cell
lines performed in the presence and absence of the drug directly identifying the effects on the self-
peptide repertoire [4]. For these assays to become useful in practice, it is necessary to establish
what distinguishes a safe drug from a drug that can induce a treatment-limiting IM-ADR. In this
study, we have used in silico approaches to identify drugs on the market that have structural simi-
larities to abacavir and performed in vitro binding and elution experiments to test whether these
drugs can alter the repertoire of HLA-B57:01 in a manner similar to abacavir. By comparing the
safety profile of these drugs with the detected effect on HLA binding, we propose a strategy to
identify and test a preliminary threshold for effects on HLA binding that can be considered safe.
Materials and Methods
Ethics statement
This study was approved by the Australian Bone Marrow Donor Registry as the source of
healthy donor HLA-B57:01 positive and control PBMCs. In addition the use of human cells
Acyclovir-Induced Hypersensitivity
PLOS ONE | DOI:10.1371/journal.pone.0124878 May 29, 2015 2 / 15
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was approved by the ethics committee of the Institute for Immunology and Infectious Diseases,
Murdoch University, Australia. The use of HLA-B57:01 and B58:01 cell lines was as previ-
ously described by our group (see reference 4).
Database Searching
The screening of molecules is based on the assumption that 'structurally similar molecules
might have similar biological property' [7]. A screening protocol was built containing a series
of filters to carry out the virtual screening using 2D and 3D similarity, taking into account the
location of pharmacophoric groups (Fig 1). Virtual screening of the ZINC database [8], a free
database of commercially-available compounds, was carried out as described below. The 2D
structure of the reference molecule abacavir was screened against the ZINC database using a
concatenated fingerprint consisting of the 'FP2' and 'FP4' fingerprints of Mychem (http://
mychem.sourceforge.net/). The degree of structural similarity was calculated using a Tanimoto
score[9], considering a threshold of 0.60 and above.
Additionally, 3D similarity-based screening was carried out for approximately 10,000 mole-
cules obtained from 2D-based similarity screening results using a superimposition algorithm
developed previously [10]. The 3D similarity score was calculated in terms of root mean square
deviation (rmsd), by optimization of an objective function that takes into account the distance
between the atoms. This score reflects the quality of the superposition between the query mole-
cule and the database entries. Using a threshold of rmsd 1.5 Å, around 2,000 compounds were
scored, and for each compound up to 100 computed conformers were considered for the com-
parison. Furthermore, a special preferred screening condition was defined in order to retain
Fig 1. The workflow of the virtual screening protocol for screening of similar drugs to abacavir.
doi:10.1371/journal.pone.0124878.g001
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certain pharmacophoric features obtained from known structure activity relationship (SAR).
In previous docking studies [4], it was observed that the purine core of abacavir is important
for binding. Accordingly, the purine core was marked as one of the chemical features to be re-
tained in the screened molecules. A similar criterion was established for the hydroxyl group of
abacavir, which is also hypothesized to be involved in binding. Moreover, the spatial arrange-
ment of the aromatic ring is assumed to be an important recognition element. On the basis of
these filtering criteria, a total of 153 compounds were investigated further. Finally, with refer-
ence to the chemical tractability and the quality of superimposition, 54 compounds were select-
ed for docking studies.
Molecular Docking
To further filter the hit list, docking studies were carried out using GOLD 5.2 [11] and the GOLD-
Score scoring function. In the present study, the abacavir-inducedMHC complex (PDB ID:
3UPR) was selected as the input structure for docking studies. Residues around the original ligand
(radius 10.0 Å) were defined as the active site, which also covered the peptide binding area of the
MHCmolecule. Docking studies of the previously selected 54 compounds were performed using
the standard parameters and further inspected visually using PyMOL (The PyMOLMolecular
Graphics System, Version 1.5.0.4 Schrödinger, LLC.). Based on reasonable binding conforma-
tions, seven candidates were forwarded as leads for experimental validation (Fig 2). The analysis
of the docking results is provided in (S2 & S2 Fig; with reference to abacavir and acyclovir).
Drugs
Roscovitine, cladribine, acyclovir, arranon, minoxidil, sangivamycin and bohemine were pur-
chased from Fisher Scientific (Pitsburgh, PA). Abacavir sulfate was purchased from LGM
Pharma (Nashville, TN). Each drug was initially re-suspended at 30 mg/mL in 50% dimethyl-
sulfoxide (DMSO) in phosphate buffered saline (PBS, pH 7.2). The drugs were then suspended
in the final assay at a concentration of 2, 1 or 0.5 mg/mL containing 3.3% DMSO in PBS (de-
noted as vehicle).
HLA Binding Assays
Quantitative assays to measure the binding affinity of peptides to purified HLA-B57:01 mole-
cules based on the inhibition of binding of a radiolabeled standard peptide were performed as
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previously described [12]. Briefly, 1–10 nM of radiolabeled peptide was co-incubated at room
temperature with 1 nM to 1 μM purified HLA-B57:01 in the presence of 1–3 μM human
β2-microglobulin (Scripps Laboratories; San Diego, CA) and a mixture of protease inhibitors.
After a 2-day incubation, binding of the radiolabeled peptide to the MHC class I molecule was
determined by capturing MHC/peptide complexes on Greiner Lumitrac 600 microplates (Grei-
ner Bio-One; Monroe, North Carilina) coated with the W6/32 antibody, and measuring bound
counts per minute (cpm) using the TopCount microscintillation gamma counter (PerkinElmer;
Waltham, Massachusetts). For competition assays, the concentration of peptide yielding IC50
of the binding of the radiolabeled peptide was calculated. Peptides were typically tested at six
different concentrations covering a 100,000-fold dose range.
For direct binding studies in the absence of a competitor peptide, a purified peptide with se-
quence KAAKYRVSV was ordered from Synthetic Biomolecules (San Diego, CA) and its affin-
ity for either HLA-B57:01 or HLA-B58:01 was tested in the presence or absence of abacavir,
or acyclovir, in a dose dependent manner.
Peptide Elution and Identification
For elution studies, 4–5 x 109 cells from the HLA-B57:01 single allele transfected 721.221
cell line were used [13]. Treated cells were incubated with acyclovir at a concentration of
500 μg/mL for 14 hr at 37°. Cells were harvested and stored at -80°C. Upon thawing, cells were
lysed using cell lysis buffer in the presence of protease inhibitors. The lysate was centrifuged at
100,000 x g for 1 hr and the supernatant was collected and passed through a 0.8/0.2 μm filter
(VWR International, TX). The filtrate was collected and passed through a sepharose CL-4B
(Sigma-Aldrich, MO) column to capture any remaining materials in the lysate that may clog
the antibody columns. The filtrate was then passaged through a column packed with protein A
sepharose (PAS) beads (sigma) coated with MK-D6 (MTCC HB-3, VA) antibody which served
to as an irrelevant antibody (specific for the mouse class II molecule, I-Ad) used to derive a neg-
ative control peptide extract. Next, the filtrate was passed through a second PAS column coated
with W6/32 antibody (MTCC HB-95) which captures HLA class I molecules. The columns
were washed sequentially with: 1) 2 column volumes of lysis buffer, 2) 20 column volumes of
20 mM Tris-HCL (pH 8.0, 150 mMNaCl), 3) 20 column volumes of 20 mM Tri-HCl (pH 8.0,
1.0 M NaCl), and 4) 20 column volumes of 20 mM Tris-HCl (pH 8.0), and then eluted with 4
column volumes of 0.2 M glacial acetic acid. The eluted peptides were then collected and spun
at 3,500g at 4°C until 98% of the solution had passed through Millipore ultrafiltration units
with a 3,500 Da cut-off (EMDMillipore, MA) to exclude β-2 microglobulin. The filtrate was
then collected and concentrated in vacuo for LC-MS analysis.
Peptides were analyzed by nanoflow high-performance liquid chromatography (HPLC)/
microelectrospray ionization, coupled directly to a Thermo Fisher Scientific FT-ICR mass
spectrometer, equipped with a home-built, front-end electron transfer dissociation (FETD)
source [14]. An aliquot of peptide sample was taken to dryness in a vacuum concentrator. Pep-
tides were amidated in a solution that contained 1M histamine-HCl (20 μL) in 1M pyridine-
HCl buffer and 0.1M EDC in pyridine-HCl buffer [15]. The solution was sonicated for 3 hours
before being dried in a vacuum concentrator and then reconstituted in 0.1% acetic acid.
Data were acquired as previously described [16]. In brief, a pre-column, loaded with 5×107 to
2×108 cell equivalents of HLA-B57:01 eluted peptides was connected with polytetrafluoroethylene
tubing (0.06-in. o.d. and 0.012-in. i.d.; Zeus Industrial Products) to the end of an analytical HPLC
column (360 μm o.d.×50 μm i.d.) containing 6–7 cm of C18 reverse-phase packing material (5-μm
particles; YMC). Peptides were eluted through a laser-pulled electrospray tip directly into the mass
spectrometer with an Agilent 1100 series binary LC pump at a flow rate of ~60 nL/min. Elution
Acyclovir-Induced Hypersensitivity
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gradients utilized were as follows: solvent A was 0.1 M acetic acid in H2O and solvent B was 70%
acetonitrile. For the analyses, collisionally activated dissociation (CAD) and ETD fragmentation
were performed sequentially on the same parent ions. The FETD reagent was azulene and the ion-
ion reaction time was set to 45 ms. The instrument was operated in a data-dependent mode where
a full-scan mass spectrum was acquired with the high resolution mass analyzer and this was then
followed by sequential acquisition of CAD and/ or ETDMS/MS spectra in the linear trap on the
top 5 or 10 most abundant, non-excluded ions observed in the full-scan spectrum.
Data fromMS/MS experiments were searched against the Swiss-Prot [17] human database
using the Open Mass Spectrometry Search Algorithm software [18] to generate a list of candi-
date peptide sequences. Instrument parameters included a precursor mass tolerance of ±0.01
Da and a monoisotopic fragment ion mass tolerance of ±0.35 Da. Database search parameters
allowed variable modifications for phosphorylation on serine, threonine, and tyrosine residues
and oxidation of methionine. In addition for the histamine reaction data the variable modifica-
tion for histamine to aspartic acid, glutamic acid, and the C-terminus were included. Database
assignments of drug-specific peptides were confirmed by manual interpretation of the corre-
sponding MS/MS spectra.
Culture and Detection of Drug Responsive T Cells
Drug responsive short-term T cell lines were produced from cryopreserved PBMC, as previ-
ously described [19]. Briefly, HLA-B57:01 positive PBMC samples were cultured in the pres-
ence or absence of 10 μg/mL abacavir (pure substance; GSK) or 10 μg/mL acyclovir (Sigma-
Aldrich) for 14 days. From day 3 and every 3 days, 50% of media was replaced and 20 U/ml of
recombinant human interleukin (IL)-2 (Peprotech) was added to cultures. To enumerate drug
responsive T cells, C1R.B57 antigen presenting cells (APC) were cultured overnight with or
without 10 μg/mL abacavir, or 10 μg/mL acyclovir, and then washed. Treated or untreated
C1R.B57 APC were added at a 1:10 ratio to PBMC and incubated at 37°C/5% CO2 for six
hours, in the presence of 20 μg/mL Brefeldin-A (Sigma-Aldrich) for the final 4 hours. Samples
were surface labeled for CD4 and CD8 expression on ice and then fixed and permeabilized for
the detection of intra-cellular IFN-γ, as previously described [19]. Abacavir responsive cells
were then detected using flow cytometry (Gallios; Beckman Coulter). Lymphocytes were gated
on the basis of forward and side scatter properties. The lymphocyte gate was then gated for
CD8, but not CD4, positivity using a Boolean logic gate. The frequency of CD8 and IFN-γ dou-
ble positive cells was determined using Kaluza software (Beckman Coulter).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego,
CA). Data were analyzed using column statistics, t-test, Mann-Whitney U-test or one-sided
Fisher’s exact test. All p-values< 0.05 were considered significant.
Results
Computational Identification of Drugs Predicted to have a Similar Effect
to Abacavir on HLA-B*57:01 Binding
We set out to identify drugs currently in use that are structurally similar to abacavir and there-
fore could show a similar effect on HLA-B57:01 binding. The screening process was initiated
by filtering approximately 3.5 million entries from the ZINC database using a 2D similarity-
based method (Fig 1). Since the chemical space was huge, a strict threshold of 0.60 Tanimoto
score was considered. The subset was further reduced using 3D similarity and presence of the
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pharmacophoric groups as additional filtering criteria. Based on the degree of superimposition
and chemical tractability, the enriched subset was further analyzed through molecular docking
and visual inspection.
Previous analysis[4] of the abacavir-exposed HLA-B57:01 complex suggested that interac-
tions of residues Ser166, Asp114, Ile124 and Tyr74 of the MHCmolecule and the purine core
of abacavir play a crucial role in the molecular recognition. Hence, this information was uti-
lized for pose selection from the molecular docking studies.
Visual inspection was carried out based on the pre-analyzed receptor-ligand interactions of
abacavir-induced MHC complex, maximum chemical similarity between the reference struc-
ture and the database entries and, lastly, the occupancy of the ligand in the active site defined.
This led to the identification of seven drugs as candidates for further analysis (Fig 2).
In Vitro Binding Studies to Identify Peptides that Bind with High Affinity to
HLA-B*57:01 in the Presence of Acyclovir
Next, we tested if the presence of each drug could enhance the HLA-B57:01 binding affinity
for three 9-mer peptides with a C-terminal valine known to bind HLA-B57:01 with high affin-
ity only in the presence of abacavir. This screening indicated that acyclovir lead to a small but
consistent increase in the HLA-B57:01 affinity of these three peptides (S3 Fig), while the other
compounds had a smaller or no effect at all. We then screened a larger number of 9-mer pep-
tides ending with V in dose dependent concentration of acyclovir and also used abacavir as a
positive control. As expected from our previous studies [4], the affinity of HLA-B57:01 for
each of these peptides increase significantly in the presence of abacavir (Fig 3). For most of the
peptides, acyclovir had a qualitatively similar, albeit much smaller, effect (Fig 3).
Positional scanning combinatorial library analysis
Since acyclovir was predicted to be similar to abacavir in terms of its capacity to interact with
HLA-B57:01, we next determined if the effect of acyclovir could have been detected when
Fig 3. Effects of abacavir and acyclovir on HLA-B*57:01 binding specificity. Specific peptides with a
terminal valine that showed an increased affinity for HLA-B*57:01 in the presence of abacavir were tested.
Values are represented as geometric mean with 95% CI of two independent runs in triplicates, analyzed for
statistical significance by Mann-Whitney U test comparing log IC50 values vs. vehicle; p < 0.05 was
considered significant (*p < 0.05; **p < 0.01; ***p < 0.001).
doi:10.1371/journal.pone.0124878.g003
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screening a set of 9-mer PSCPL systematically scanning the effect of each naturally occurring
amino acid at each position in a 9-mer peptide. This approach was successful in identifying
that abacavir primarily impacts the interaction between the peptide C-terminal residue and the
HLA-B57:01 molecule [4].
When the PSCPL was screened, it was found that the greatest increases in HLA-B57:01 af-
finity, in the context of acyclovir treatment, were associated with the presence of C, I and V at
the C-terminus (Fig 4). For each of these residues, a 2-fold increase in B57:01 affinity was ob-
served in the presence of the acyclovir compared to a 10-fold increase in affinity for I and V
peptides previously observed in the presence of abacavir [4]. The C-terminal peptide library
with the highest affinity for HLA-B57:01 in the presence of acyclovir was observed for isoleu-
cine (478 nM in the presence of acyclovir vs. 1470 nM in the absence) followed by valine and
cysteine (Table 1). In conclusion, the data in this section have shown that the PSCPL could de-
tect an acyclovir-induced effect on the specificity of HLA-B57:01 binding based on modified
affinity for peptides with C, I and V terminal residues.
Follow up on PSCPL with individual C-terminal I and C peptides
To be able to induce an immune response that can lead to an ADR, a peptide has to bind MHC
molecules with a high enough affinity to ensure efficient presentation to T cells. For this reason
we were particularly interested in investigating ligands with C-terminal residues associated
with affinities, as measured with the PSCPL, of 5,000 nM or better. In addition to peptides with
C-terminal V that we had already tested in our initial screening (Fig 3) we also observed a sig-
nificant increase in B57:01 binding affinity for I and C terminal residues in the presence of
acyclovir (Table 1). Accordingly, we selected 7 peptides with either C or I at their C-terminus
and tested them for binding to B57:01 with and without acyclovir. The only requirement for
these peptides was that they had a C or I at P9 but were otherwise random in sequence. Binding
to HLA-B57:01 in the presence of abacavir was used as a positive control. As shown in Fig 5,
of the 7 peptides ending in I, only two showed a dose dependent increase in affinity for
HLA-B57:01. By contrast, all seven peptides showed increased affinities in the presence of aba-
cavir. None of the peptides ending in C showed any change in HLA-B57:01 affinity in the
presence of acyclovir (S4 Fig). Thus, these data show that the acyclovir-induced effect on
HLA-B57:01 specificity detected with the PSCPL could also be detected in the context of indi-
vidual peptides with isoleucine but not for those with cysteine C-termini.
Fig 4. Effects of acyclovir (2 mg/mL) on the affinity of C-terminal residues for HLA-B*57:01. Values are
represented as geometric mean with 95% CI of the fold difference between vehicle/acyclovir treatment. The
experiment was run 6 times with each run performed in triplicates. Analyzed for statistical significance by
column statistics; p < 0.05 was considered significant (*p < 0.05; **p < 0.01; ***p < 0.001). The most
pronounced affinity increases for HLA-B*57:01 in the presence of 2 mg/mL of acyclovir were found for
peptides with a cysteine, isoleucine and valine at the C-terminus.
doi:10.1371/journal.pone.0124878.g004
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Direct drug binding assays
All binding data reported so far relied on detecting replacement of a labeled competitor pep-
tide. To measure direct binding of peptide to MHC we synthesized a variant of peptide KAA-
KIRVSV in which the isoleucine residue in position 5 was exchanged with a tyrosine residue to
enable radiolabeling. The variant peptide with the tyrosine substitution bound with six-fold
lower affinity in the presence of 1 mg/mL acyclovir (IC-50: 10040 ± 2336 for KAAKYRVSV
vs. 1560 ± 865 for KAAKIRVSV; results represented ad median ± SD). The direct peptide
binding assay demonstrated that peptide KAAKYRVSV binds with increasing efficiency to
HLA-B57:01 in a dose-dependent manner (Fig 6A). As expected, the presence of abacavir was
associated with an even greater effect, resulting in an up to 5-fold increase in bound peptides,
while acyclovir increased the level of bound peptides 2-fold (Fig 6A). In contrast, as a control,
when binding to the structurally similar HLA-B58:01 molecule was examined, KAAKYRVSV
was found to be unaffected by the presence of either acyclovir or abacavir (Fig 6B).
Treatment of HLA-B*57:01 Cell Line with Acyclovir Results in an
Increased Number of Peptides with C-terminal Isoleucine
Our binding studies with the combinatorial libraries predicted that HLA-B57:01 in the pres-
ence of acyclovir would favor presentation of peptides with cysteine, isoleucine or valine at
their C-terminus, and this was validated for individual peptides for isoleucine and valine. To
test this prediction, we eluted peptides from an HLA-B57:01 single allele transfected cell line
in the presence or absence of acyclovir. The identity of eluted peptides was determined by mass
Table 1. Peptide affinity (nM) for HLA-B*57:01 in the presence of 2 mg/mL acyclovir.





















Bold indicates peptides that showed a signiﬁcant increase in afﬁnity for HLA-B*57:01 in the presence of
acyclovir (as shown in Fig 4) and also had an IC50  5,000 nM. Values are derived from the medians of six
independent measurements run in triplicates.
doi:10.1371/journal.pone.0124878.t001
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spectrometry and comparing the gathered spectra against the Swiss-Prot human database as
described in the Methods. Of note, the MS detection by itself cannot distinguish isoleucine
from leucine residues, so distinguishing peptides with these sequences relies on the database
comparison to human proteins. We identified 169 and 95 unique sequences from drug treated
and untreated samples, respectively, and an additional 91 sequences that were present in both
samples (S1 Table). Next, we analyzed the eluted peptide sequences for specific characteristics.
No peptides with a C-terminal cysteine or valine were identified in either of the samples (S1
Table). In contrast, we did identify a higher number of peptides with a C-terminal isoleucine in
the presence of acyclovir (twelve) compared to the untreated samples (four), with three of the
peptides being present in both samples (S1 & S2 Tables). However, this difference was not sig-
nificant (p = 0.073, Fisher’s exact test).
For the nine peptides with a C-terminal isoleucine that were initially exclusively identified
in the drug treated sample in the combined MS and database search, we performed targeted
queries to determine if they could have been present in the untreated sample. These searches
revealed that one peptide with the assigned sequence RARQLNYTI was exclusively found in
the drug treated sample in that it was not selected for MS2 in the untreated sample, nor was it
seen in the MS1 scan when searched for by accurate mass. When this peptide was ordered and
tested for its capacity to bind treated and untreated HLA-B57:01 it was found that binding
was indeed improved by about two-fold in the presence of acyclovir (S5 Fig; IC-50: 13.7 ± 1.3
for vehicle vs. 7.1 ± 1.0 for 0.5 mg/mL acyclovir; Mean ± SEM, p< 0.01). These studies illus-
trate that the elution of peptides from HLA-B57:01 transfected cell lines in the presence of
acyclovir is consistent with the in vitro PSCPL and individual peptide data.
Fig 5. Effects of abacavir and acyclovir on HLA-B*57:01 binding specificity. Specific peptides with a
terminal isoleucine that showed an increased affinity for HLA-B*57:01 in the presence of abacavir were
tested. Values are represented as geometric mean with 95%CI of two independent runs in triplicates,
analyzed for statistical significance by Mann-Whitney U test comparing log IC50 values vs. vehicle; p < 0.05
was considered significant (*p < 0.05; **p < 0.01; ***p < 0.001).
doi:10.1371/journal.pone.0124878.g005
Acyclovir-Induced Hypersensitivity
PLOS ONE | DOI:10.1371/journal.pone.0124878 May 29, 2015 10 / 15
Acyclovir is unable to Induce in vitro HLA-B*57:01 Restricted T-cell
Responses
We and others have previously reproduced abacavir specific CD8+ T cell responses in short-
term lines from 100% of HLA-B57:01+ abacavir unexposed healthy blood donors [20]. To in-
vestigate whether acyclovir has the ability to induce T-cell responses in a HLA restricted man-
ner in vitro, we compared the effect of acyclovir, abacavir or no drug treatment, on the
generation of drug specific short term lines, using PBMC from two healthy HLA-B57:01 posi-
tive, HIV-negative and abacavir unexposed donors. Drug specific responses were assessed fol-
lowing re-stimulation of 14 day cultures with a drug treated or untreated HLA-B57:01 stably
transfected antigen presenting cell line, C1R.B57, and the frequency of CD8 positive / IFN-γ
positive T-cells was quantitated using flow cytometry. As expected, we detected an expanded
population of CD8 positive / IFN-γ positive T-cells in abacavir primed lines restimulated by
abacavir-treated C1R.B57 (Fig 7B), but not following re-stimulation with untreated (Fig 7A) or
acyclovir-treated C1R.B57 (Fig 7C), in two of two donors. We could not detect any acyclovir
specific response in PBMC cultures primed with acyclovir (Fig 7D), cultured for 14 days and
re-stimulated with acyclovir treated C1R.B57 in two of two donors. Similarly, we could not de-
tect any stimulation of acyclovir primed cultures using untreated or abacavir treated C1R.B57
in two of two donors (Fig 7D). This suggests that under in-vitro conditions, acyclovir does not
have the capacity to stimulate T-cells.
Fig 6. Acyclovir and abacavir alter the binding specificity of HLA-B*57:01. The peptide KAAKYRVSV
was radiolabeled and tested for binding to HLA-B*57:01 in increasing doses of acyclovir and abacavir.
Values are represented as geometric mean with 95% CI of four experimental runs in triplicates. Analysed by
statistical significance by one-sided MannWhitney test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0124878.g006
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Discussion
There is an unmet need for sensitive and specific pre-clinical screening methodologies to effi-
ciently identify drug candidates that might cause IM-ADRs in early stages of drug design and
development. Recently, our group and others have identified a new mechanism of how the
small molecule abacavir interacts exclusively with HLA B57:01 molecules, leading to an alter-
ation in the HLA-B57:01 peptide binding repertoire, and a drug-associated immune mediated
T-cell hypersensitivity reaction [4–6]. The assays utilized in these studies have the potential to
act as screening tools to assess drugs for similar effects. To assess if there is indeed a correlation
between clinical safety and the readouts of these assays, we here examined drugs with estab-
lished clinical safety profiles that are structurally similar to abacavir. Of the panel of drugs test-
ed, we found that acyclovir had the strongest effect and did alter the binding specificity and
ligand repertoire of HLA-B57:01 in a qualitatively similar fashion as abacavir, although quan-
titatively to a much lower degree. Similar to abacavir, acyclovir is a guanosine analogue cur-
rently used as an antiviral agent. Acyclovir, however, has a robust safety record with almost 30
years of post-marketing experience, unlike abacavir has not been associated with any treatment
limiting IM-ADRs except for isolated case reports [21–24]. Thus, the changes induced by acy-
clovir to the binding specificity and ligand repertoire of HLA-B57:01 are not in themselves
sufficient to trigger IM-ADRs.
Quantitatively, the presence of acyclovir led to 2–3 fold increases in binding affinity as mea-
sured by IC50 and to the presentation of a single peptide that was clearly absent in untreated
cells. In contrast, abacavir led to 1,000 fold increases in IC50 values for individual peptides and
large numbers of peptides presented exclusively in the presence of the drug (such as 15 peptides
with a C-terminal valine). Given the safety profile of acyclovir, we suggest that effects of the
magnitude observed here are below the threshold of what can be considered safe in terms of
Fig 7. PBMC from a healthy HLA-B*57:01 positive donor (Donor 1) where primed with abacavir at day
0, cultured for 14 days and then restimulated 1:10 with (A) HLA-B*57:01 single antigen line (C1R.B57),
(B) with O/N abacavir treated C1R.B57 (C1R.B57.ABC) or (C) with O/N acyclovir treated C1R.B57 (C1R.
B57.ACY). Antigen activated cells were detected by ICS for IFN-γ production and CD8+/ IFN-γ T-cells
quantitated using flow cytometry. (D) PBMC from two healthy HLA-B*57:01 positive donors were either
primed with abacavir (ABC primed), primed with acyclovir (ACY primed) or had no treatment (Control. PBMC
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induction of an altered peptide repertoire based IM-ADR. Thus, this study establishes a first es-
timate of a threshold of what can be considered a safe in the assays utilized here.
Based on our binding studies, one could have expected that peptides with a C-terminal Cys-
teine would preferentially be presented and eluted in the presence of acyclovir. However, pep-
tides with c-terminal cysteine residues are poor substrates for both proteasomal cleavage and
TAP binding, and are found at low frequencies in peptide elution studies (e.g. 2/935 = 0.03%)
[25]. Given the small effect of acyclovir, we were not surprised that it did not overcome this
barrier to presentation.
In addition to the binding and elution assays, we also performed cell culture studies in
which we examined if we can induce drug responsive T-cells in HLA-B57:01+ PBMCs cultures
from abacavir naive healthy individuals. These studies suggest that abacavir, but not acyclovir,
can induce drug response T cells after a two-week culture. Such cell culture assays have the ad-
vantage of requiring less specialized instrumentation and reagents compared to the radio-
immuno binding assay or the mass spectrometry coupled elution experiments.
One limitation of our study was that, in the absence of identifying a drug that showed strong
abacavir-like effects, we cannot say for certain that the structure based drug selection strategy
applied was successful. Future studies will examine if different selection strategies or screening
compounds at a large scale might have identified drugs with similar or larger effects than acy-
clovir. Furthermore, most drugs that were predicted to have structural similarity to abacavir
showed no effect in our binding assays. Given that we are unable to measure direct binding of
the drugs to HLA, we cannot know if these results are due to the drugs not binding to
HLA-B57:01. We do consider such lack of binding the most likely hypothesis given the rather
constrained binding site of abacavir in the crystal structure, which could mean that even similar
drugs are too different from abacavir to fit into the specific site. More importantly, we consider
such lack of binding to be a more likely explanation compared to the alternative hypothesis
that the drugs do bind to HLA-B57:01 but do not alter the binding specificity of the molecule,
which seems structurally unlikely given the fact C-terminal peptide residue side chains do over-
lap with the site occupied by abacavir.
In conclusion, we have here compared different in vitro readouts that could be potential in-
dicators of HLA-associated IM-ADRs. Notably, the clinically safe drug acyclovir which is struc-
turally very similar to abacavir showed qualitative evidence of interaction with HLA-B57:01
but little or no quantitative or functional effect. We suggest that these in vitro approaches show
great promise as a pre-clinical screening strategy if they can be developed further to establish
safety thresholds that can be validated with high sensitivity and specificity to predict altered
self-repertoire mediated IM-ADRs.
Supporting Information
S1 Fig. (left) The structure of the co-crystallized abacavir-peptide-MHCmolecule (PDB ID:
3UPR): abacavir shown in green and peptide (HSITYLLPV) shown in red; (right) structure
of the acyclovir-peptide-MHC molecule predicted by molecular docking studies (GOLD
5.2) acyclovir shown in blue and peptide (HSITYLLPV) shown in red. Figure prepared by
using PyMOL (The PyMOLMolecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.).
(TIF)
S2 Fig. Illustration of the binding patterns between the MHCmolecule and acyclovir pre-
dicted by molecular docking studies.Hydrogen bond interactions between the Ile 124 (MHC
molecule) main chains and acyclovir is represented by green dashed arrow. Hydrogen bond in-
teractions between side-chains of Ser 116, Asp 114 (MHC molecule) and acyclovir is repre-
sented by blue dashed arrow. Pi interactions between the Trp147, Tyr74 of the MHCmolecule
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and acyclvir is shown in orange line. Figure prepared by using Discovery Studio software (ver-
sion 3.1; Accelrys Inc., USA).
(TIF)
S3 Fig. Effect of seven drugs on binding specificity of HLA-B57:01. Three different peptides
were tested for binding to HLA-B57:01 in competitive binding assays as described previously
[26,27]. Values are represented as geometric mean with 95% CI of one experimental run in
quadruplicates, analyzed for statistical significance by paired one-tailed parametric t-test com-
paring log IC50 values vs. vehicle; p< 0.05 was significant only in the presence of acyclovir.
(TIF)
S4 Fig. Effects of abacavir and acyclovir on HLA-B57:01 binding specificity. Specific pep-
tides with a terminal cysteine were tested for their binding affinity in the presence of abacavir
or acyclovir. Values are represented as geometric mean with 95% CI of two independent runs
in triplicates, analyzed for statistical significance by Mann-Whitney U test comparing log IC50
values vs. vehicle; p< 0.05 was considered significant (p< 0.05; p< 0.01; p< 0.001).
(TIF)
S5 Fig. Effects of acyclovir on HLA-B57:01 binding specificity for RARQLNYTI. Values
are represented as Mean ± SEM and analyzed for statistical significance by Mann-Whitney U
test comparing IC50 values vs. vehicle; p< 0.05 was considered significant (p< 0.01).
(TIF)
S1 Table. List of peptides eluted in the presence and absence of acyclovir.
(DOCX)
S2 Table. Number of peptides with C terminal isoleucine in ACI treated vs. untreated cells.
(DOCX)
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